Vernalis receives ‘non-approvable’ letter from FDA

Vernalis Plc and its partner Endo Pharmaceuticals Inc have been told by the US Food and Drug Administration that their proposed treatment for the prevention of menstrual migraine has not yet demonstrated a clinically meaningful benefit.